SureTrader
Interactive Brokers Advertisement
Home > Boards > US Listed > Medical - Drugs >

AVEO Pharmaceuticals, Inc. (AVEO)

AVEO RSS Feed
Add AVEO Price Alert      Hide Sticky   Hide Intro
Moderator: mick, Apophis
Search This Board: 
Last Post: 12/11/2017 2:16:15 PM - Followers: 120 - Board type: Free - Posts Today: 0

AVEO ONCOLOGY, Inc. (AVEO) 

Company website: 
http://www.aveooncology.com/

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted therapies for cancer and related diseases. The company's pipeline of product candidates include Tivozanib, a vascular endothelial growth factor (VEGF) to optimize VEGF blockade; Ficlatuzumab, a hepatocyte growth factor (HGF) inhibitory antibody, which has completed Phase II trial that inhibits the activity of the HGF/c-Met pathway; and AV-203, an anti-ErbB3 specific monoclonal antibody that has completed a Phase I dose escalation study. Its development programs also comprise AV-380, a humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; and the AV-353 platform for the potential treatment of pulmonary arterial hypertension. The company has strategic partnerships with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent's Hospital Sydney Limited; Biogen Idec International GmbH; and Kyowa Hakko Kirin Co., Ltd. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is based in Cambridge, Massachusetts.

   





Product pipeline candidates include Tivozanib, Ficlatuzumab, AV-203, AV-353 and AV-380.
 

AV-380 (GDF-15 Program)

In August 2015, AVEO announced an exclusive, worldwide license agreement with Novartis for the development and commercialization of AVEO’s first-in-class, potent, humanized inhibitory antibody targeting growth differentiation factor 15 (GDF15), AV-380, and related antibodies, including modified or derivative forms of any such antibody.

GDF15 is a pro-inflammatory cytokine whose elevated circulating levels have been correlated with cachexia in cachectic cancer patients and several animal models of cancer cachexia. Current evidence suggests that a pro- inflammatory state may be responsible for many of the symptoms associated with cachexia, a complex metabolic syndrome characterized by malnutrition and severe involuntary weight loss due to the loss of muscle and fat tissue, as well as the clinical manifestation of anemia, inflammation and suppression of immune functions.

Preclinical data show that inhibition of GDF15 results in a switch from catabolism to anabolism, suggesting that GDF15 inhibition with AV-380 may reverse the effects of cachexia.
Cachexia is a serious and common complication in patients with advanced cancer and other chronic diseases. It affects some five million individuals in the United States.

Tivozanib

Tivozanib, is a potent, selective, long half-life inhibitor of all three vascular endothelial growth factor (VEGF) receptors that is designed to optimize VEGF blockade while minimizing off-target toxicities.

AVEO remains encouraged by the clinical outcomes from its Phase 2 and Phase 3 studies in renal cell carcinoma and the efficacy and tolerability profile that tivozanib may offer to patients suffering from this challenging disease. In addition, promising biomarker results were observed in a Phase 2 study of tivozanib in colorectal cancer.

In August of 2014, AVEO regained all rights to tivozanib. In November 2014, AVEO entered into an option agreement with Ophthotech to investigate tivozanib for the potential treatment of non-oncologic diseases of the eye. In August 2015, AVEO entered into an exclusive license agreement with Pharmstandard OJSC for the development, manufacturing and commercialization of tivozanib in the territories of Russia, Ukraine and the Commonwealth of Independent States (CIS), for all indications excluding ocular conditions. The Company is actively pursuing partnerships in Europe to advance the development and commercialization of tivozanib in solid tumors.

AVEO is interested in collaborating with potential partners who share our vision for cancer drug development and positively impacting patients’ lives. Please contact AVEO aveobd@aveooncology.com to discuss partnership opportunities with AVEO’s development pipeline.

European Medicines Agency (EMA), has approved on 8/28/17  FOTIVDA™ (tivozanib) for approval as a treatment (Solid Dose) for patients with advanced renal cell carcinoma (RCC)
 

Ficlatuzumab

Ficlatuzumab (formerly known as AV-299) is a potent hepatocyte growth factor (HGF) inhibitory antibody that binds to the HGF ligand with high affinity and specificity to inhibit HGF/c-Met biological activities.

AVEO and Biodesix, Inc. have a worldwide agreement to develop and commercialize ficlatuzumab, with VeriStrat®, a serum protein test that is commercially available to help physicians guide treatment decisions for patients with advanced non-small cell lung cancer (NSCLC). Under the terms of the agreement, AVEO and Biodesix are conducting a proof-of-concept study of ficlatuzumab in combination with erlotinib in advanced NSCLC patients selected using BDX001, a serum protein test similar to the VeriStrat test.

An exploratory analysis from AVEO’s Phase 2 study in first-line NSCLC suggested that VeriStrat was prognostic for outcome in the epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor (TKI)-treated patients and predicted differential treatment benefit for the combination of ficlatuzumab plus TKI over TKI alone. The predictive effect was observed in both progression-free survival and overall survival endpoints
 

AV-203

AVEO scientists have demonstrated through the use of our Human Response Platform™ the importance of ErbB3 in promoting tumor growth. An increasing body of evidence also implicates the activation of ErbB3 in tumorigenesis and the development of resistance to anti-cancer agents. AV-203 is a clinical-stage ErbB3 (HER3) inhibitory antibody candidate designed to inhibit both ligand-dependent and ligand-independent ErbB3 signaling. ErbB3 is a receptor that is typically expressed in many human cancers, and AV-203 has demonstrated preclinical activity in a number of different tumor models including breast, head and neck, lung, ovarian and pancreatic cancers.

AVEO has successfully completed a Phase 1 safety study showing no dose limiting toxicities at maximum dose of 20mg/kg and CLIA (Clinical Laboratory Improvements Amendment) validation has been completed for a biomarker for potential patient selection.

AV-353

AV-353 is the Company’s potent, selective, high affinity inhibitory antibody specific to Notch 3. The Notch 3 signaling pathway is important in cell-to-cell communication involving gene regulation mechanisms that control multiple cell differentiation processes during the entire life cycle. Scientific literature has implicated the Notch 3 receptor pathway in multiple diseases, including cancer, cardiovascular diseases and neurodegenerative conditions. Publications, including Nature Medicine (2009), have implicated the Notch 3 pathway in Pulmonary Arterial Hypertension (PAH). PAH is a rare and life-threatening disorder that affects approximately 250,000 people worldwide and is caused by enlargement of the arterial walls in small arteries between the heart and the lungs, resulting in restricted blood flow.

Current treatments in PAH focus only on controlling symptoms by avoiding vasoconstriction and increasing vasodilation of vessels and do not reverse the underlying cause of the disease. In contrast, with the results of a recently concluded preclinical animal studies supported by AVEO, AV-353 has generated a growing body of preclinical data that supports AV-353’s ability to potentially reverse the disease phenotype, which would represent a potential disease-modifying approach to treatment. AVEO is currently seeking a partner to develop and commercialize AV-353 worldwide in PAH.

For additional information, or to inquire about potential partnering opportunities, please contact Nikhil Mutyal (nmutyal@aveooncology.com).

 
www.aveopharma.com
Shares Outstanding   110,363,000
Insider Ownership 17%
Institutional + Mutual Fund Ownership  58%
20 Full Time Employees
http://investor.aveooncology.com/phoenix.zhtml?c=219651&p=irol-irhome
 
  
One Broadway 14th Floor
Cambridge, MA 02142

Investor Relations
Phone: 617-588-1960
E-mail: ir@aveooncology.com

 
SureTrader
Interactive Brokers Advertisement
AVEO
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
AVEO News: AVEO Oncology Announces Clinical Updates to Tivozanib and Ficlatuzumab Programs 12/07/2017 07:00:00 AM
AVEO News: Securities Registration Statement (simplified Form) (s-3) 11/30/2017 05:34:31 PM
AVEO News: Securities Registration: Employee Benefit Plan (s-8) 11/30/2017 05:34:02 PM
AVEO News: Statement of Changes in Beneficial Ownership (4) 11/22/2017 04:29:53 PM
AVEO News: Initial Statement of Beneficial Ownership (3) 11/22/2017 04:24:40 PM
PostSubject
#3087  Sticky Note AVEO Oncology Announces FOTIVDA® (tivozanib) Approved in the Maple tree 08/28/17 06:46:30 AM
#1839  Sticky Note $AVEO recent news/filings mick 11/17/15 10:42:39 AM
#3502   A new 52 week high is brewing sometime Apophis 12/11/17 02:16:15 PM
#3501   http://www.wallstreetmorning.com/2017/12/11/aveo-pharmaceuticals-inc-aveo-trader Apophis 12/11/17 02:12:49 PM
#3500   Watch for the UK/NICE and FDA P3 data twistedfreak 12/08/17 06:36:00 AM
#3499   Tivozanib (FOTIVDA®) is an oral, once-daily, vascular endothelial Apophis 12/07/17 09:11:23 AM
#3498   Ficlatuzumab Ficlatuzumab (formerly known as AV-299) is a potent Apophis 12/07/17 09:10:31 AM
#3497   I do remember. I’ll get in into this Rogerthat1 12/07/17 08:56:38 AM
#3496   LMAO Roger. Is it June yet? Remember what twistedfreak 12/07/17 06:31:46 AM
#3495   Lmao. Getting ugly here Rogerthat1 12/07/17 02:41:27 AM
#3494   http://services.corporate-ir.net/SEC/Document.Service?id=P3VybD1hSFIwY0RvdkwyRnd Ithinkimdoingitwrong 12/01/17 11:17:09 AM
#3493   LOTS OF STALLS? Apophis 12/01/17 08:18:53 AM
#3492   http://www.barchart.com/cheatsheet.php?sym=AVEO mick 12/01/17 05:17:48 AM
#3491   http://www.thestreetpoint.com/2017/11/29/mind-blowing-stocks-aveo-pharmaceutical Ithinkimdoingitwrong 11/29/17 10:21:37 AM
#3489   Let's talk at end of Q2'18 kid twistedfreak 11/21/17 06:57:14 PM
#3488   This was going to be at $5 few Rogerthat1 11/21/17 06:03:05 PM
#3487   ~~Severance and Change in Control Agreement; dated November n3m3sis 11/20/17 09:33:37 AM
#3486   Thank you, what you said made sense, so gi197845 11/19/17 11:55:27 PM
#3485   My thoughts are this is going to be harry crumb 11/19/17 11:51:16 PM
#3484   That was from JTaylor68 on the INNV board. gi197845 11/19/17 11:49:49 PM
#3483   Good about the revenue stream, thank you. gi197845 11/19/17 11:48:33 PM
#3482   Product sales have begun in Europe last week Apophis 11/19/17 10:30:53 PM
#3481   What is that from? Lynx7 11/19/17 09:48:41 PM
#3480   Is this an Uh-oh? What are Harry Crumbs thoughts? gi197845 11/18/17 11:25:35 PM
#3479   day trading groups are done , if you Apophis 11/17/17 03:13:14 PM
#3478   Yes if a day trader collaborates to buy Apophis 11/17/17 10:17:46 AM
#3477   SEC: Day Trader Charged in Brokerage Account Takeover n3m3sis 11/17/17 06:04:09 AM
#3476   Up all day today, decent day. Tomorro brings harry crumb 11/16/17 05:08:42 PM
#3475   A 26k + after hours buy for 3.01! harry crumb 11/15/17 05:31:02 PM
#3474   THEY ARE GOING AFTER THE DAY TRADERS THAT Apophis 11/15/17 12:27:43 PM
#3473   Aveo's Fotivda launched in Germanyhttp://www.seekingalpha.com/news/3312504 Ithinkimdoingitwrong 11/15/17 12:14:03 PM
#3472   Its the day traders that do the most Apophis 11/15/17 10:08:56 AM
#3471   Got to love the MM here as buying Apophis 11/15/17 09:53:02 AM
#3470   More selling coming today as more news hits. Apophis 11/15/17 09:13:48 AM
#3469   Hopefully today's the day! BigWorm129 11/15/17 06:31:14 AM
#3468   Aveo will squeeze the shorts dry! Matter of harry crumb 11/14/17 07:05:35 PM
#3467   http://www.eusapharma.com/news/fotivda-tivozanib-now-licensed-in-the-european-un Apophis 11/14/17 04:17:30 PM
#3465   Sounds like patience is wearing thin with many twistedfreak 11/14/17 01:23:27 PM
#3464   Yep...pretty sad with all the potential here. Bullwinkle77 11/14/17 01:11:01 PM
#3463   repeated coordinated short attacks are bleeding out liquidity, Apophis 11/14/17 01:03:55 PM
#3462   This is the reason I got out. This Bullwinkle77 11/14/17 12:19:30 PM
#3460   It happens... but this little run is nothing Bullwinkle77 11/10/17 01:06:52 PM
#3459   wow, mistake. your choice, gl. $$$ harry crumb 11/10/17 12:46:12 PM
#3458   yup lots of damage done by that huge Apophis 11/08/17 02:09:28 PM
#3457   Got out even this morning.. this one is broken Bullwinkle77 11/08/17 02:03:09 PM
#3456   As Warren Buffet says.......... n3m3sis 11/08/17 09:37:56 AM
#3455   it should be trading much higher before any Apophis 11/08/17 08:57:19 AM
#3454   You cannot keep a good stock down! n3m3sis 11/08/17 06:28:43 AM
#3453   back up to 4 area coming. $$$ harry crumb 11/07/17 10:02:30 PM
#3452   I would be happier to see the trading Apophis 11/07/17 02:52:48 PM
#3451   all new lots purchased this am “green”! loaded harry crumb 11/07/17 01:19:09 PM
#3450   Ok, I’m willing to share with friends. BJ_Cooper 11/07/17 09:52:23 AM
PostSubject